|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
US7438907B2
(en)
|
2002-11-15 |
2008-10-21 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
SI2906252T1
(sl)
|
2012-10-12 |
2017-10-30 |
Adc Therapeutics Sa |
Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
|
|
WO2014057118A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10751346B2
(en)
|
2012-10-12 |
2020-08-25 |
Medimmune Limited |
Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
|
|
AU2013328625B2
(en)
*
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
FR3008408B1
(fr)
*
|
2013-07-11 |
2018-03-09 |
Mc Saf |
Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
SG11201601763SA
(en)
|
2013-09-20 |
2016-04-28 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
WO2015052533A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
WO2015191615A2
(en)
*
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
JP6451133B2
(ja)
|
2014-08-01 |
2019-01-16 |
株式会社リコー |
異常検知装置、異常検知方法、異常検知システム、及びプログラム
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
GB201506399D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506409D0
(en)
|
2015-04-15 |
2015-05-27 |
Williams David G And Berkel Patricius H C Van And Howard Philip W |
Humanized anti-axl antibodies and their conjugates
|
|
GB201506394D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506388D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506405D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
TN2017000440A1
(en)
|
2015-04-17 |
2019-04-12 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
GB201507827D0
(en)
|
2015-05-07 |
2015-06-17 |
Adc Therapeutics Sarl |
Diagnostic test
|
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
CA2988115A1
(en)
|
2015-06-03 |
2016-12-08 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
GB201513607D0
(en)
|
2015-07-31 |
2015-09-16 |
Feingold Jay M |
Pyrrolobenzodiazepine-antibody conjugates
|